HC Wainwright Analysts Boost Earnings Estimates for Alector

Alector, Inc. (NASDAQ:ALEC - Free Report) - Research analysts at HC Wainwright upped their Q1 2025 earnings per share (EPS) estimates for shares of Alector in a report issued on Thursday, February 27th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($0.41) per share for the quarter, up from their previous estimate of ($0.42). HC Wainwright currently has a "Buy" rating and a $7.00 price target on the stock. The consensus estimate for Alector's current full-year earnings is ($1.88) per share. HC Wainwright also issued estimates for Alector's Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($1.63) EPS, FY2026 earnings at ($1.66) EPS, FY2027 earnings at ($1.41) EPS and FY2028 earnings at ($1.22) EPS.

A number of other brokerages have also recently weighed in on ALEC. Stifel Nicolaus cut Alector from a "buy" rating to a "hold" rating and set a $4.00 price target for the company. in a research report on Monday, December 16th. Mizuho cut Alector from an "outperform" rating to a "neutral" rating and decreased their target price for the stock from $9.00 to $2.50 in a research report on Tuesday, December 17th. Cantor Fitzgerald reissued an "overweight" rating on shares of Alector in a research report on Tuesday, November 26th. Bank of America cut shares of Alector from a "neutral" rating to an "underperform" rating and reduced their price objective for the stock from $9.00 to $1.00 in a research note on Wednesday, December 4th. Finally, Morgan Stanley lowered shares of Alector from an "equal weight" rating to an "underweight" rating and lowered their target price for the company from $10.00 to $3.00 in a research note on Tuesday, November 26th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Alector has an average rating of "Hold" and a consensus price target of $3.75.

Alector Price Performance

NASDAQ:ALEC traded up $0.10 during trading hours on Monday, reaching $1.55. The company's stock had a trading volume of 650,084 shares, compared to its average volume of 716,171. The company has a market cap of $153.58 million, a price-to-earnings ratio of -0.91 and a beta of 0.61. Alector has a one year low of $1.30 and a one year high of $7.10. The business's 50-day moving average is $1.75 and its 200-day moving average is $3.43.

Alector (NASDAQ:ALEC - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.59. The company had revenue of $54.24 million during the quarter, compared to the consensus estimate of $20.41 million. Alector had a negative net margin of 257.54% and a negative return on equity of 108.77%.

Institutional Investors Weigh In On Alector

Several hedge funds have recently modified their holdings of ALEC. RA Capital Management L.P. bought a new position in Alector during the fourth quarter worth $18,324,000. JPMorgan Chase & Co. increased its holdings in shares of Alector by 64.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,728,823 shares of the company's stock worth $12,716,000 after purchasing an additional 1,072,298 shares during the period. 5AM Venture Management LLC acquired a new position in shares of Alector during the fourth quarter valued at about $1,882,000. Renaissance Technologies LLC lifted its stake in shares of Alector by 63.0% in the fourth quarter. Renaissance Technologies LLC now owns 915,738 shares of the company's stock valued at $1,731,000 after buying an additional 353,988 shares during the period. Finally, Almitas Capital LLC acquired a new stake in Alector during the fourth quarter worth about $538,000. 85.83% of the stock is owned by institutional investors.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.